Empagliflozin in Heart Failure with a Preserved Ejection
Fraction

J 2021

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

ANKER, S.D., J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI et. al.

Basic information

Original name

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Authors

ANKER, S.D. (guarantor), J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE-VALENZUELA, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, D. SIM, Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, P. CARSON, C. S. P. LAM, N. MARX, C. ZELLER, N. SATTAR, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER

Edition

New England Journal of Medicine, Waltham, Massachussetts Medical Society, 2021, 0028-4793

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Slovenia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 176.079

RIV identification code

RIV/00216224:14110/21:00122279

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1056/NEJMoa2107038

UT WoS

000691622000001

Keywords in English

Heart Failure; Empagliflozin; Preserved Ejection Fraction

Abstract

V originále

BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

Citovat

ANKER, S.D., J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE-VALENZUELA, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, D. SIM, Jindřich ŠPINAR, I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, P. CARSON, C. S. P. LAM, N. MARX, C. ZELLER, N. SATTAR, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2021, vol. 385, No 16, p. 1451-1461. ISSN 0028-4793. Available from: https://dx.doi.org/10.1056/NEJMoa2107038.

@article{1790339,
   author = {Anker, S.D. and Butler, J. and Filippatos, G. and Ferreira, J. P. and Bocchi, E. and Bohm, M. and BrunnerandLa, Rocca H. P. and Choi, D. J. and Chopra, V. and ChuquiureandValenzuela, E. and Giannetti, N. and GomezandMesa, J. E. and Janssens, S. and Januzzi, J. L. and GonzalezandJuanatey, J. R. and Merkely, B. and Nicholls, S. J. and Perrone, S. V. and Pina, I. L. and Ponikowski, P. and Senni, M. and Sim, D. and Špinar, Jindřich and Squire, I. and Taddei, S. and Tsutsui, H. and Verma, S. and Vinereanu, D. and Zhang, J. and Carson, P. and Lam, C. S. P. and Marx, N. and Zeller, C. and Sattar, N. and Jamal, W. and Schnaidt, S. and Schnee, J. M. and Brueckmann, M. and Pocock, S. J. and Zannad, F. and Packer, M.},
   article_location = {Waltham},
   article_number = {16},
   doi = {http://dx.doi.org/10.1056/NEJMoa2107038},
   keywords = {Heart Failure; Empagliflozin; Preserved Ejection Fraction},
   language = {eng},
   issn = {0028-4793},
   journal = {New England Journal of Medicine},
   title = {Empagliflozin in Heart Failure with a Preserved Ejection Fraction},
   url = {https://www.nejm.org/doi/10.1056/NEJMoa2107038},
   volume = {385},
   year = {2021}
}

TY  - JOUR
ID  - 1790339
AU  - Anker, S.D. - Butler, J. - Filippatos, G. - Ferreira, J. P. - Bocchi, E. - Bohm, M. - Brunner-La, Rocca H. P. - Choi, D. J. - Chopra, V. - Chuquiure-Valenzuela, E. - Giannetti, N. - Gomez-Mesa, J. E. - Janssens, S. - Januzzi, J. L. - Gonzalez-Juanatey, J. R. - Merkely, B. - Nicholls, S. J. - Perrone, S. V. - Pina, I. L. - Ponikowski, P. - Senni, M. - Sim, D. - Špinar, Jindřich - Squire, I. - Taddei, S. - Tsutsui, H. - Verma, S. - Vinereanu, D. - Zhang, J. - Carson, P. - Lam, C. S. P. - Marx, N. - Zeller, C. - Sattar, N. - Jamal, W. - Schnaidt, S. - Schnee, J. M. - Brueckmann, M. - Pocock, S. J. - Zannad, F. - Packer, M.
PY  - 2021
TI  - Empagliflozin in Heart Failure with a Preserved Ejection Fraction
JF  - New England Journal of Medicine
VL  - 385
IS  - 16
SP  - 1451-1461
EP  - 1451-1461
PB  - Massachussetts Medical Society
SN  - 00284793
KW  - Heart Failure
KW  - Empagliflozin
KW  - Preserved Ejection Fraction
UR  - https://www.nejm.org/doi/10.1056/NEJMoa2107038
N2  - BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
ER  -

ANKER, S.D., J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE-VALENZUELA, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, D. SIM, Jindřich ŠPINAR, I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, P. CARSON, C. S. P. LAM, N. MARX, C. ZELLER, N. SATTAR, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. \textit{New England Journal of Medicine}. Waltham: Massachussetts Medical Society, 2021, vol.~385, No~16, p.~1451-1461. ISSN~0028-4793. Available from: https://dx.doi.org/10.1056/NEJMoa2107038.

Detailed Information on Publication Record